Arcadia Biosciences, Inc.

For the period ended Dec 31, 2024. Filed Mar 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 25, 2025

RKDA$0.16-3.5%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share data)

	As of December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$4,242	$6,518
Short-term investments	—	5,124
Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 as of December 31, 2024 and 2023	1,175	506
Inventories, net — current	904	837
Assets held for sale	—	51
Note receivable — current	1,894	—
Prepaid expenses and other current assets	931	807
Current assets of discontinued operations — GoodWheat	96	1,129
Total current assets	9,242	14,972
Property and equipment, net	41	70
Right of use assets	137	792
Inventories, net — noncurrent	—	196
Intangible assets, net	39	39
Note receivable — noncurrent	3,966	—
Other noncurrent assets	92	164
Noncurrent assets of discontinued operations — GoodWheat	—	3,472
Total assets	$13,517	$19,705
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses	$2,108	$1,910
Amounts due to related parties	30	58
Operating lease liability — current	155	852
Other current liabilities	270	270
Current liabilities of discontinued operations — GoodWheat	—	500
Total current liabilities	2,563	3,590
Operating lease liability — noncurrent	—	155
Common stock warrant and option liabilities	2,731	1,257
Other noncurrent liabilities	2,000	2,000
Total liabilities	7,294	7,002
Commitments and contingencies (Note 15)
Stockholders’ equity:
Common stock, $0.001 par value—150,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 1,364,940 and 1,285,337 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively.	65	65
Additional paid-in capital	285,036	284,515
Accumulated other comprehensive income	—	101
Accumulated deficit	(278,878)	(271,840)
Total Arcadia Biosciences stockholders’ equity	6,223	12,841
Non-controlling interest	—	(138)
Total stockholders' equity	6,223	12,703
Total liabilities and stockholders’ equity	$13,517	$19,705

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.